10/31/2025
In a recent study published in The New England Journal of Medicine, investigators reported the final 23-year analysis of the European Randomized Study of Screening for Prostate Cancer (ERSPC), quantifying benefits, harms, and practice implications.
The 23-year ERSPC trial reveals that sustained, protocolized PSA testing lowers prostate cancer deaths and improves the benefit-to-harm ratio, supporting a shift toward risk-based, patient-centered screening strategies.
Long-term, protocolized PSA screening reduces deaths from prostate cancer but increases testing, biopsies, and diagnoses, many for low-risk disease. Shared decision-making should incorporate individual risk, baseline PSA levels, life expectancy, and personal values. Risk calculators and magnetic resonance imaging (MRI) pathways can help decouple an elevated PSA from the need for immediate biopsy, while active surveillance can spare treatment for low-risk tumors.
The study noted that very low baseline or age-60 PSA strongly predicts lifetime risk, supporting longer intervals or screening cessation in low-risk men. Overall, targeted screening can preserve mortality benefits, lessen overdiagnosis and overtreatment, and better align care with what matters to patients.
Read the article at:
After 23 years of follow-up, the European Randomized Study of Screening for Prostate Cancer (ERSPC) confirmed a 13% lower prostate cancer mortality with PSA testing and an improved harm–benefit ratio over time. Risk-based screening could sustain mortality gains while reducing overdiagnosis and unn...